NCT06002789View on ClinicalTrials.gov

Safety and Efficacy of PD-1 ± mFOLFOX6 Neoadjuvant Therapy in Local Advanced sMPCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

September 1, 2027

Study Completion Date

December 1, 2028

Conditions
Multiple CancerColorectal Cancer
Interventions
DRUG

MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy

For MSI-H/MSS (dMMR/pMMR) mixed sMPCC, a combination of neoadjuvant chemotherapy with mFOLFOX6 and immunotherapy with PD-1 monoclonal antibody are applied.

DRUG

All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy

For all-MSI-H (dMMR) sMPCC, single-drug PD-1 monoclonal antibody immunotherapy is applied.

Trial Locations (1)

Unknown

RECRUITING

The Sixth Affiliated Hospital, Sun Yatsen University, Guangzhou

All Listed Sponsors
lead

Sixth Affiliated Hospital, Sun Yat-sen University

OTHER